coumarin has been researched along with diclofenac in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
| Dai, R; Liu, Y; She, M; Wu, Z | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
| Barbosa, G; Ceschi, MA; Dantas, RF; Dardenne, LE; de Salles, CMC; Guedes, IA; Lima, LM; Lopes, JPB; Lüdtke, DS; Ruaro, TC; Senger, MR; Silva, L; Silva-Jr, FP; Zimmer, AR | 1 |
| Fujita, K; Kamataki, T; Nakayama, K; Nohmi, T; Tsuruma, K; Yamada, M; Yamazaki, Y | 1 |
| Chiba, K; Kobayashi, K; Shimada, N; Urashima, K | 1 |
| Obach, RS; Walsky, RL | 1 |
| Ekman, S; Fransson-Steen, R; Hagbjörk, AL; Löfgren, S; Terelius, Y | 1 |
| Anzenbacher, P; Anzenbacherová, E; Masek, V; Veinlichová, A | 1 |
| Hirode, M; Imazawa, T; Kiyosawa, N; Miyagishima, T; Mizukawa, Y; Nagao, T; Omura, K; Ono, A; Shimizu, T; Uehara, T; Urushidani, T | 1 |
16 other study(ies) available for coumarin and diclofenac
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
Topics: Cytochrome P-450 Enzyme Inhibitors; Enzyme Activation; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Molecular Structure; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
Topics: | 2019 |
Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Topics: Alkylating Agents; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Ethanolamines; Genetic Engineering; Humans; Midazolam; Mixed Function Oxygenases; Mutagenicity Tests; NADP; NADPH-Ferrihemoprotein Reductase; Nitrosamines; Recombinant Proteins; Salmonella typhimurium; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Baculoviridae; Cells, Cultured; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; DNA, Complementary; Ethanolamines; Gene Expression; Humans; Insecta; Isoenzymes; Mephenytoin; Midazolam; Nitrophenols; Pharmaceutical Preparations; Phenacetin; Rats; Substrate Specificity; Testosterone; Tumor Cells, Cultured | 2002 |
Validated assays for human cytochrome P450 activities.
Topics: Amodiaquine; Bupropion; Coumarins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Drug Design; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Humans; In Vitro Techniques; Isoenzymes; Mass Spectrometry; Microsomes, Liver; Phenacetin; Recombinant Proteins; Reproducibility of Results | 2004 |
Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison.
Topics: Amiodarone; Animals; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; DNA, Complementary; Ethanolamines; Female; Humans; Kinetics; Lauric Acids; Male; Mephenytoin; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Microsomes, Liver; Mixed Function Oxygenases; NADP; Nitrophenols; Oxidoreductases, N-Demethylating; Oxygen; Paclitaxel; Phenacetin; Rats; Sex Factors; Species Specificity; Substrate Specificity; Testosterone | 2004 |
Comparison of "high throughput" micromethods for determination of cytochrome P450 activities with classical methods using HPLC for product identification.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Humans; Male; Mixed Function Oxygenases; Testosterone | 2005 |
Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to humans.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Chemical and Drug Induced Liver Injury; Coumarins; Data Interpretation, Statistical; Diclofenac; Gene Expression; Hepatocytes; Humans; Male; Microscopy, Electron, Scanning; Oligonucleotide Array Sequence Analysis; Rats; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Toxicogenetics | 2008 |